Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NVCT

NVCT - Nuvectis Pharma, Inc. Stock Price, Fair Value and News

$8.42-0.33 (-3.77%)
Market Closed

13/100

NVCT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

13/100

NVCT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$6.87

Target 3M

$7.73

Target 6M

$7.3

NVCT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NVCT Price Action

Last 7 days

-1.9%

Last 30 days

9.6%

Last 90 days

26.8%

Trailing 12 Months

32.0%

NVCT RSI Chart

NVCT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NVCT Valuation

Market Cap

215.7M

Price/Earnings (Trailing)

-8.5

Price/Sales (Trailing)

209.4

Price/Free Cashflow

-14.87

NVCT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$6.87

Target 3M

$7.73

Target 6M

$7.3

NVCT Fundamentals

NVCT Revenue

Revenue (TTM)

1.0M

Rev. Growth (Yr)

61.17%

Rev. Growth (Qtr)

27.2%

NVCT Earnings

Earnings (TTM)

-25.4M

Earnings Growth (Yr)

-79.68%

Earnings Growth (Qtr)

-17.81%

NVCT Profitability

Return on Equity

-105.69%

Return on Assets

-71.31%

Free Cashflow Yield

-6.72%

NVCT Investor Care

Shares Dilution (1Y)

32.58%

Diluted EPS (TTM)

-1.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025858.0K904.0K1.0M0
2024810.0K961.0K890.0K847.0K
2023199.0K259.0K475.0K637.0K
202240.3K76.5K112.8K149.0K
20210004.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Nuvectis Pharma, Inc.

NVCT
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
 CEO
 WEBSITEnuvectis.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES11

Nuvectis Pharma, Inc. Frequently Asked Questions

NVCT is the stock ticker symbol of Nuvectis Pharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Nuvectis Pharma, Inc. is 215.68 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check NVCT's fair value in chart for subscribers.

The fair value guage provides a quick view whether NVCT is over valued or under valued. Whether Nuvectis Pharma, Inc. is cheap or expensive depends on the assumptions which impact Nuvectis Pharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NVCT.

As of Wed Jan 28 2026, NVCT's PE ratio (Price to Earnings) is -8.5 and Price to Sales (PS) ratio is 209.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NVCT PE ratio will change depending on the future growth rate expectations of investors.